Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine and Celecoxib in Hospitalized Moderate-to-Severe COVID-19
NCT05085574Phase 2Withdrawn
- Sponsor
- Leidos
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of famotidine, celecoxib oral solution in coronavirus disease 2019 (COVID-19), sponsored by Leidos. Planned start Feb 2023; status: withdrawn.
02
Drugs
famotidinecelecoxib oral solution
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05085574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085574.